Melanoma Marker Antibody (HMB45): sc-59305

Melanoma Marker Antibody (HMB45) is a mouse monoclonal IgG1 kappa light chain antibody that detects Melanoma Marker in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-Melanoma Marker antibody (HMB45) recognizes a neuraminidase-sensitive oligosaccharide side chain of a glycoconjugate found in immature melanosomes, specifically in junctional and blue nevus cells. Melanoma Marker (HMB45) antibody plays a significant role in studying the development and progression of malignant melanoma, a serious form of skin cancer arising from melanocytes. Melanoma Marker monoclonal antibody (HMB45) helps researchers understand complex glycosylated chains that influence cell signaling and interactions within the tumor microenvironment. These glycosylated structures affect how melanoma cells evade immune response and metastasize, making them important targets for therapeutic intervention. Anti-Melanoma Marker antibody (HMB45) is available in non-conjugated forms and conjugated versions with agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing flexibility for diverse experimental needs. Given melanoma′s increasing incidence and association with ultraviolet radiation exposure, Melanoma Marker (HMB45) monoclonal antibody serves as an essential tool for advancing research and developing effective treatments for this aggressive cancer.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Melanoma Marker Antibody (HMB45) References:

1. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.  |  de Vries, TJ., et al. 1999. Br J Cancer. 80: 883-91. PMID: 10360670
2. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker.  |  Salazar-Onfray, F., et al. 2002. Br J Cancer. 87: 414-22. PMID: 12177778
3. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.  |  Stoitchkov, K., et al. 2003. Melanoma Res. 13: 587-93. PMID: 14646622
4. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences.  |  Guerquin-Kern, JL., et al. 2004. Biomed Eng Online. 3: 10. PMID: 15068483
5. Epidermoid cyst with infiltrative malignant melanoma in the cerebellopontine angle.  |  Meng, FG., et al. 2006. J Clin Neurosci. 13: 669-72. PMID: 16815016
6. Melanoma control: few answers, many questions.  |  Dunbar, R., et al. 2006. N Z Med J. 119: U2172. PMID: 16998573
7. Sentinel-node biopsy in melanoma.  |  Balch, CM. and Cascinelli, N. 2006. N Engl J Med. 355: 1370-1. PMID: 17005955
8. Clear cell variant of diffuse large B-cell lymphoma: a case report.  |  Manxhuka-Kerliu, S., et al. 2011. J Med Case Rep. 5: 182. PMID: 21569513
9. Melanoma marker and breast carcinoma.  |  Lin, CS. 1990. Am J Clin Pathol. 94: 669-70. PMID: 2288610
10. Breast carcinoma with positive results for melanoma marker (HMB-45). HMB-45 immunoreactivity in normal and neoplastic breast.  |  Bonetti, F., et al. 1989. Am J Clin Pathol. 92: 491-5. PMID: 2552794
11. Immunohistochemical and histochemical tools in the diagnosis of amelanotic melanoma.  |  van Duinen, SG., et al. 1984. Cancer. 53: 1566-73. PMID: 6365305
12. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody.  |  Fernando, SS., et al. 1994. Pathology. 26: 16-9. PMID: 8165017

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Melanoma Marker Antibody (HMB45) has 18 citations in a variety of scientific publications.

Primary antibodies like Anti-Melanoma Marker Antibody (HMB45) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Melanoma Marker Antibody (HMB45) Specifications

Alternate Product Name: Melanoma Marker

Product Clone Name: HMB45

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: pigmented melanoma metastases from lymph nodes

Epitope Species: human

Product Reactivity/Detection: a neuraminidase sensitive oligosaccharide side chain of a glycoconjugate present in immature melanosomes in junctional and blue nevus cells

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 18 citations in various scientific publications

Available Conjugates/Forms for Melanoma Marker Antibody (HMB45): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin